Critical Role of Diagnostic Markers in Differentiating CLL from Other Hematological Malignancies

Dr Delgado is head of the Oncoimmunotherapy Unit at Hospital Clínic Barcelona. The commentary covers the diagnostic process for CLL, the compulsory marker panel, why biopsy and bone marrow aspiration are not required, and the common genomic aberrations used for prognosis.

Target Audience

Healthcare Professionals 

Learning Objectives

  • Increased knowledge on the specific diagnostic markers of CLL
  • Describe the specific cellular markers associated with CLL and their relevance in diagnosis and patient stratification
  • Increased knowledge on the updated clinical practice guidelines
  • Summarize current treatment guidelines for CLL from the NCCN and other relevant organizations to ensure compliance with the most current standard-of-care practice guidelines, as well as the clinical trial data for these updated guidelines

This activity is supported by an educational grant from Eli Lilly.

Course summary

Course opens: 
09/07/2026
Course expires: 
09/30/2031
Cost:
$0.00
Dr. Julio Delgado

Dr. Julio Delgado

Head, Oncoimmunotherapy Unit, Hospital Clínic, Barcelona (HCB)
Consultant Haematologist, Hospital Clínic, Barcelona (HCB)
Researcher, IDIBAPS Biomedical Research Institute
Associate Professor, University of Barcelona

Accreditation for this activity has now expired

Price

Cost:
$0.00
Please login or register to take this course.